NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.
The financing was raised by a new investor that Bennani declined to identify, and will be used to accelerate clinical trials for its technology. Since its inception, it has raised $15 million.
The Great River, NY-based company, founded in 2010, is building a blood-based assay that can separate rare fetal cells in maternal blood. Its technology is based on antibody called 4B9 licensed from AdnaGen. 4B9 recognizes and binds to an epitope expressed by a type of nucleated fetal nucleated red blood cell, or fNRBC.
KellBenX plans to launch its test in late 2014 or early 2015.